---
title: SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
nct_id: NCT04374370
overall_status: NO_LONGER_AVAILABLE
sponsor: AdventHealth
study_type: EXPANDED_ACCESS
primary_condition: COVID
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04374370.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04374370"
ct_last_update_post_date: 2021-05-06
last_seen_at: "2026-05-12T07:04:51.514Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

**Official Title:** Severe Acute Respiratory Syndrome Coronavirus 2 of the Genus Betacoronavirus (SARSCoV2) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

**NCT ID:** [NCT04374370](https://clinicaltrials.gov/study/NCT04374370)

## Key Facts

- **Status:** NO_LONGER_AVAILABLE
- **Study Type:** EXPANDED_ACCESS
- **Lead Sponsor:** AdventHealth
- **Conditions:** COVID, SARSCoV2 Convalescent Plasma
- **CT.gov Last Update:** 2021-05-06

## Brief Summary

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.

## Detailed Description

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel COVID-19 virus. Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus. The purpose of this trial is to provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.

## Eligibility

- **Minimum age:** 6 Years
- **Maximum age:** 99 Years
- **Sex:** ALL

```
Inclusion Criteria:

* Ages 6 and up
* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age); or willing and able to provide assent as required per Institutional Review Board (IRB) prior to performing study procedures.
* Must have laboratory confirmed COVID-19 positive test
* Must have severe or immediately life-threatening COVID-19

Severe disease is defined as:

1. dyspnea
2. respiratory frequency ≥ 30/min
3. blood oxygen saturation ≤ 93%
4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or
5. lung infiltrates \> 50% within 24 to 48 hours

   Life-threatening disease is defined as:
6. respiratory failure
7. septic shock, and/or
8. multiple organ dysfunction or failure

Exclusion Criteria:

* Known contraindication to transfusion or history of prior reactions to transfusion of blood products
```

## Interventions

- **SARSCoV2 Convalescent Plasma** (BIOLOGICAL) — Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.

## Locations (1)

- AdventHealth Orlando, Orlando, Florida, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.adventhealth orlando|orlando|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04374370.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04374370*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*